Bispecific Antibodies

  • Roland E. Kontermann

Table of contents

  1. Front Matter
    Pages i-xvii
  2. Gerhard Moldenhauer
    Pages 29-46
  3. Diego Ellerman, Justin M. Scheer
    Pages 47-63
  4. Christoph Stein, Ingo Schubert, Georg H. Fey
    Pages 65-82
  5. Dafne Müller, Roland E. Kontermann
    Pages 83-100
  6. Patrick Chames, Daniel Baty
    Pages 101-114
  7. John Löfblom, Fredrik Y. Frejd
    Pages 115-133
  8. Patrick Koenig, Germaine Fuh
    Pages 187-198
  9. Chien-Hsing Chang, Edmund A. Rossi, Robert M. Sharkey, David M. Goldenberg
    Pages 199-216
  10. Christian Kellner, Matthias Peipp, Thomas Valerius
    Pages 217-241
  11. Patrick A. Baeuerle, Gerhard Zugmaier, Dominik Rüttinger
    Pages 273-287
  12. Horst Lindhofer, Juergen Hess, Peter Ruf
    Pages 289-312
  13. Bruno Robert, Christel Larbouret, David Azria, Jean-Pierre Mach, André Pèlegrin
    Pages 313-326
  14. Dirk M. Nettelbeck
    Pages 327-347
  15. Archana Parashar, Susmita Sarkar, Advaita Ganguly, Sai Kiran Sharma, Mavanur R. Suresh
    Pages 349-367
  16. Back Matter
    Pages 369-373

About this book


The concept of using bispecific antibodies for cancer therapy by retargeting immune effector cells was developed more than 25 years ago. However, initial clinical studies were rather disappointing mainly due to low efficacy, severe side effects and the immunogenicity of the bispecific antibodies. A deeper understanding of effector cell biology and especially developments in the field of antibody engineering has led to the generation of new classes of bispecific antibodies capable of circumventing many of these obstacles. Furthermore, new applications were established for bispecific antibodies, such as pre-targeting strategies in radioimmunotherapy and dual targeting approaches in order to improve binding, selectivity and efficacy.

In this book, the different means of generating bispecific antibodies are described, with an emphasis on recombinant formats, and information on the various applications of bispecific antibodies, e.g. in cellular cancer immunotherapy, radioimmunotherapy and pretargeting strategies, but also on emerging applications such as dual targeting strategies, i.e., the simultaneous inhibition of two targets (cytokines, receptors, etc.) are provided. This book is intended for a broad readership in the field of antibody engineering, mainly from the pharmaceutical and biotechnology sector, but also including academic researchers working in this field.


Cancer therapy Hybridoma Immunoglobulin Immunotherapy Radioimmunotherapy T-cells

Editors and affiliations

  • Roland E. Kontermann
    • 1
  1. 1.Inst. Zellbiologie und ImmunologieUniversität StuttgartStuttgartGermany

Bibliographic information